Dasatinib

Name: Dasatinib
Brand: Selleck Chemicals
SKU: S1021
Rating: 5 (396 reviews)

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

396 publications

CAS No. 302962-49-8

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Selleck's Dasatinib has been cited by 396 publications

Nature, 2020, 10.1038/s41586-020-2884-6

PubMed: 33149299 ( click the link to review the publication )

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

J Neuroinflammation, 2021, 18(1):18

PubMed: 33422097 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2021, 84:103625

PubMed: 33617955 ( click the link to review the publication )

Inflammation, 2021, 10.1007/s10753-020-01408-5

PubMed: 33527321 ( click the link to review the publication )

J Virol, 2021, JVI.00180-21

PubMed: 33597213 ( click the link to review the publication )
Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Gastroenterology, 2020, 159(3):956-968.e8

PubMed: 32485177 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5842

PubMed: 33203880 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 9e60470

PubMed: 33226337 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )
Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2730

PubMed: 32977582 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3869

PubMed: 33371412 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):20343

PubMed: 33230163 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16616

PubMed: 33024173 ( click the link to review the publication )
Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Am J Pathol, 2020, S0002-9440(20)30550-2

PubMed: 33307038 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )
Signal Transduct Target Ther, 2020, 5(1):139

PubMed: 32792487 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(8):e8849

PubMed: 31464373 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )
Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

J Clin Med, 2019, 8(4)E455

PubMed: 30987403 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

Pharmacol Res, 2019, 147:104357

PubMed: 31356863 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17104

PubMed: 31745115 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

J Acquir Immune Defic Syndr, 2019, 82(4):407-415

PubMed: 31658184 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )
Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):4449-4456

PubMed: 31611954 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31405946 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Am J Hum Genet, 2018, 103(6):976-983

PubMed: 30449416 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3607-3618

PubMed: 30257219 ( click the link to review the publication )

Cell Rep, 2018, 25(13):3674-3692.e10

PubMed: 30590041 ( click the link to review the publication )

Elife, 2018, 7e33304

PubMed: 30231971 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )
Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Front Immunol, 2018, 9:8

PubMed: 29403492 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Oral Oncol, 2018, 78:56-63

PubMed: 29496059 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

J Cell Sci, 2018, 131(22)jcs221788

PubMed: 30404826 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):584

PubMed: 29330550 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1081

PubMed: 30319416 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )
Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6831-6838

PubMed: 29731862 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

J Pharmacokinet Pharmacodyn, 2018, 45(3):401-418

PubMed: 29446053 ( click the link to review the publication )

Oncotarget, 2018, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Leukemia, 2017, 31(5):1253-1254

PubMed: 28465516 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )
Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Int J Cancer, 2017, 140(5):1173-1185

PubMed: 27798955 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Front Mol Neurosci, 2017, 10:418

PubMed: 29326548 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )
Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(27):43662-43677

PubMed: 28599273 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Sci Signal, 2016, 9(456):ra116

PubMed: 27899526 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )
Oncoimmunology, 2016, 5(12):e1240858

PubMed: 28123877 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1472-84

PubMed: 27364904 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Psychoneuroendocrinology, 2016, 66:138-49

PubMed: 26803529 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1862(11):2158-2167

PubMed: 27565738 ( click the link to review the publication )

Sci Rep, 2016, 6:26252

PubMed: 27188220 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45916-45925

PubMed: 27322141 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(17):24483-94

PubMed: 27016416 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2015, 35(11):2326-35

PubMed: 26359510 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: 25248068 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(9):5457-64

PubMed: 26284551 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )
Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1005

PubMed: 24434513 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Stem Cells, 2014, 32(9):2324-37

PubMed: 24806995 ( click the link to review the publication )
J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Pharmacogenet Genomics, 2014, 24(1):52-61

PubMed: 24322003 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

Cell Adh Migr, 2013, 7(4):362-9

PubMed: 23751956 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )
Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF7zSIw4OiCq	NU\yRmdrTE2VTx?=	MYnJR\|UxRTBwMECwNFch\|ryP	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7NU[wPFAoRjF5OUW2NFgxRC:jPh?=
K562	M{\ibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml76O\|IhcA>?	M4LyOmROW09?	MV7JR\|UxRTBwMECxJO69VQ>?	NFvYWHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m1OlA5OCd-MUe5OVYxQDB:L3G+
M07e	NHrpdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHrGbng4OiCq	M{n6c2ROW09?	MUnJR\|UxRTBwMECxNkDPxE1?	NEDFSpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m1OlA5OCd-MUe5OVYxQDB:L3G+
ALL3	NFy3ZZZEgXSxdH;4bYMhSXO\|YYm=	M{XNcVAvOc7:TR?=	NFzqZ444OiCq	MYLEUXNQ	MljDTWM2OD1yLkCwNFQh\|ryP	M{f4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEi5OVQxLz5zOUi4PVU1ODxxYU6=
CML	NVfLPGNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUTrS\|UyOjBibXnu	M3HGXGROW09?	NIXjNWdKSzVyPUCuNFAyKM7:TR?=	NH32SVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKxPVAyPid-MUmyNVkxOTZ:L3G+
BA/F3	NHzMOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYPxbm1[PzJiaB?=	MXnEUXNQ	NEi5O25KSzVyPU[uOVg6KM7:TR?=	NGnzRZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFY1PCd-MkOwPFg3PDR:L3G+
BA/F3	NWXU[WpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTpO\|IhcA>?	M3m2NGROW09?	MX3JcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=	NUm2dFlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwPFg3PDRpPkKzNFg5PjR2PD;hQi=>
BA/F3	M1f4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkLTO\|IhcA>?	NELucmJFVVOR	M3GxeGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1?	NFrEPFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFY1PCd-MkOwPFg3PDR:L3G+
BA/F3	NIW0RmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mmr1O\|IhcA>?	MWfEUXNQ	NI\uS4tKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2=	NXG5VnZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwPFg3PDRpPkKzNFg5PjR2PD;hQi=>
BA/F3	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4TaVVczKGh?	Mn3lSG1UVw>?	M3vRV2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6\|ryP	NVW1RmtTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NVfzNm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFPjRXk4OiCq	MnL0SG1UVw>?	MoXuTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN\|LPxE1?	NXPFPZNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1qyPFczKGh?	Mm\JSG1UVw>?	NFfVWFdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	M2L0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
BA/F3	NFe5NoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWq3NkBp	MYTEUXNQ	Mlz2TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>?	NVXMenJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NHHyTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3G4dFczKGh?	NUjnPXFGTE2VTx?=	Mm[1TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	NIDBPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLPcnBrPzJiaB?=	NXH1NIQxTE2VTx?=	NHHZTmNKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4rH[VczKGh?	NVnNdlFWTE2VTx?=	NWrYS5dqUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2=	NYfne49bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NUfkXYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NU\jVG9sPzJiaB?=	MXjEUXNQ	M361Wmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR\|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M13HfFczKGh?	MYDEUXNQ	M{DNUGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
T cell	M3;EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NELYclY4OiCq	NWP3[4NiTE2VTx?=	Mn2zTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0>	M2rpTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUW0OVEzLz5zN{G1OFUyOjxxYU6=
WiDr	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUDVXJhWPzJiaB?=	MXnEUXNQ	Ml3rTWM2OD1yLkC1NkDPxE1?	NHL3Wo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOid-MUW2NVU2OTJ:L3G+
PC3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHz3UG84OiCq	M3;NTmROW09?	M2nnVGlEPTB;MD6wNFk1KM7:TR?=	NGX3eJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOid-MUW2NVU2OTJ:L3G+
MDA-MB-231	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NET5RWI4OiCq	M2DPOmROW09?	MY\JR\|UxRTBwMEGyJO69VQ>?	NED0NlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOid-MUW2NVU2OTJ:L3G+
Hs578T	Mli1R5l1d3SxeHnjJGF{e2G7		M3vMWVczKGh?	MnvGSG1UVw>?	NWDqPIUzT0l3ME2wMlA{KM7:TR?=	MmfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
HMEC	MVXDfZRwfG:6aXOgRZN{[Xl?		NGfvdpo4OiCq	M{TWOGROW09?	M{iyXWdKPTB;MT64JO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
DU145	NIH0WGlEgXSxdH;4bYMhSXO\|YYm=		MmjTO\|IhcA>?	M1jyVWROW09?	NFXEcWRIUTVyPUCuNVYh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
U251	M4n1eGN6fG:2b4jpZ{BCe3OjeR?=		M2e2WVczKGh?	Ml7hSG1UVw>?	MX;HTVUxRTJwOEGg{txO	M2rwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
NCI60	NVruOXFoS3m2b4TvfIlkKEG\|c3H5		M4SxOFczKGh?	NGX4WnJFVVOR	MVfHTVUxRTVwNzFOwG0>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
MALME-3M	MnXIR5l1d3SxeHnjJGF{e2G7		MXu3NkBp	MVPEUXNQ	NV\JOGtlT0l3ME22MlYyKM7:TR?=	M2TNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
KM12	NHPOfFhEgXSxdH;4bYMhSXO\|YYm=		MlXKO\|IhcA>?	MYnEUXNQ	MnvES2k2OD15LkS0JO69VQ>?	M3fKN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
SW620	M3vHVmN6fG:2b4jpZ{BCe3OjeR?=		NYPKb3BrPzJiaB?=	MoC0SG1UVw>?	NELJTJJIUTVyPUiuOFMh\|ryP	NXrod2VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
RXF 393NL	MXfDfZRwfG:6aXOgRZN{[Xl?		NX3Ub5RDPCCmYYnz	M3vYVmROW09?	NVTpfYVOUUN3ME2wMlAzOTdizszN	MlLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
LXFA 983L	Ml\pR5l1d3SxeHnjJGF{e2G7		NGfpfHI1KGSjeYO=	Ml7TSG1UVw>?	M2PPbmlEPTB;MD6wOVY2KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
PRXF DU145	MkOwR5l1d3SxeHnjJGF{e2G7		MkKxOEBl[Xm\|	NXG2Xmw1TE2VTx?=	NFGzTWlKSzVyPUCuNFYzOyEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
PAXF 1657L	MWDDfZRwfG:6aXOgRZN{[Xl?		MWG0JIRigXN?	NXnCS3hLTE2VTx?=	NHzCfGFKSzVyPUCuNVIyKM7:TR?=	NH;K[209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1N\|A4PCd-MkOyOVMxPzR:L3G+
CXF 1103L	NWDxd4FoS3m2b4TvfIlkKEG\|c3H5		MV20JIRigXN?	MX3EUXNQ	NES3VHlKSzVyPUSuN\|Yh\|ryP	M2HZcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWzNFc1Lz5{M{K1N\|A4PDxxYU6=
GXF251L	M4XReGN6fG:2b4jpZ{BCe3OjeR?=		MmTWOEBl[Xm\|	NFL1d3lFVVOR	NUm0UIZmUUN3ME2yMlI2KM7:TR?=	NG\qcnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1N\|A4PCd-MkOyOVMxPzR:L3G+
NCI-H23	NFLUSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWPUU4M6PzJiaB?=	MVfEUXNQ	NXvrSpdwUUN3ME2yMlI4KM7:TR?=	M3LvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUKxNFIxLz5{M{WyNVAzODxxYU6=
HCT116	NHHQW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MojRO\|IhcA>?	MnvGSG1UVw>?	MnPCTWM2OD1{LkOg{txO	NGqyeWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyNVAzOCd-MkO1NlExOjB:L3G+
MCF7	NX3iZmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4DJc\|czKGh?	MUHEUXNQ	M4nZSmlEPTB;Mj61O{DPxE1?	NUjFWm1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
NCI-H460	M3O0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3TsTVczKGh?	M{DuPWROW09?	NEfEW3JKSzVyPUiuPVkh\|ryP	MljnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MkGwNlAoRjJ\|NUKxNFIxRC:jPh?=
DLD1	NFrzT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFXVT2E4OiCq	MVjEUXNQ	MXPJR\|UxRTRwNjFOwG0>	NW\kcVFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PjBpPkKzOVY4QTZyPD;hQi=>
NCI-H661	NYfGVZgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm\DO\|IhcA>?	M3jYRmROW09?	NVvW[Vc2UUN3ME23Mlgh\|ryP	Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OlAoRjJ\|NU[3PVYxRC:jPh?=
A549	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX36Z2xKPzJiaB?=	NVm1OZU1TE2VTx?=	NETIN41KSzVyPUiuNkDPxE1?	NX\Kd3p3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PjBpPkKzOVY4QTZyPD;hQi=>
U937	M{TrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWnCWmM1PzJiaB?=	M3zBWGROW09?	NWTpR3lxUUN3ME2xNk4zKM7:TR?=	NHXm[Wg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k3OCd-MkO1Olc6PjB:L3G+
HEK293	NH3tRXlHfW6ldHnvckBCe3OjeR?=	MkjCNVDDqM7:TR?=		NUTkb49pTE2VTx?=	NIfv[3hKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm\|LYTh[4dm\CCPeYSxJItqdmG\|ZTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB4M988US=>	NX3wTW9URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3O\|A3OTBpPkKyO\|cxPjFyPD;hQi=>
HUVEC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu5NE4yPcLizszN	MXW3NkBp	M4rBfWROW09?	NXLBWW06UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO	NXXVSm5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVM6QTNpPkKyPFU{QTl\|PD;hQi=>
HUVEC	M4PYbWZ2dmO2aX;uJGF{e2G7	MoW5NVXDqM7:TR?=	MXe3NkBp	MUXEUXNQ	M17ZWmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC\|bX;veIghdXW\|Y3zlJINmdGy\|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO	M1PObFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEWzPVk{Lz5{Mki1N\|k6OzxxYU6=
Plasmodium falciparum	NWGy[ZZQTnWwY4Tpc44hSXO\|YYm=	NI\uWYoyOMLizszN	MXKxOUBucW5?	M4XrPGROW09?	NF;GcXFKdmirYnn0d{BRdGG\|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR\|UxKG:oIEGuNVfPxE1?	NXvn[GlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVA{OzBpPkK0OVUxOzNyPD;hQi=>
PC3	NXXEU41pTnWwY4Tpc44hSXO\|YYm=	NIG2dnMxNjFizszN	NFm0OJk2KGh?	MnXQSG1UVw>?	M2PCXWlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
DU145	M3HPdGZ2dmO2aX;uJGF{e2G7	MofRNE4yKM7:TR?=	M1zSO\|UhcA>?	NFywdlZFVVOR	MYDJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
PC3	NXvKVXNNU2mwYYPlJGF{e2G7	Mk[3NE4yKM7:TR?=	MWO1JIg>	MmixSG1UVw>?	MonYTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=	M1PXPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NE[yPVc2Lz5zOUS2Nlk4PTxxYU6=
DU145	M3vEZ2tqdmG\|ZTDBd5NigQ>?	MU[wMlEh\|ryP	Ml;IOUBp	NFr5XlBFVVOR	MXjJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	NImzZ5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
PC3	MmTsT4lv[XOnIFHzd4F6	NGLBZnAxNjFizszN	MnXFOUBp	NUT1O4VzTE2VTx?=	M{TtU2lvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NXntNZl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
DU145	NWThdph2U2mwYYPlJGF{e2G7	NGTGUJkxNjFizszN	M2rL[lUhcA>?	NUX1OlljTE2VTx?=	MoO5TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O\|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?	NFrEe3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
Huh7	MmLFRY51cX[rcnHsJGF{e2G7	M1TRUVIvPSEQvF2=	NV71VZFMPCCmYYnz	MkPISG1UVw>?	MnnJTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	NX\MVoZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
C6/36	NIDFW5RCdnSrdnnyZYwhSXO\|YYm=	M3XROlIvPSEQvF2=	NGqwWo81KGSjeYO=	M2ezfGROW09?	MWfJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO	Mm\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
U937	NIqzVFBHfW6ldHnvckBCe3OjeR?=	MXmxJO69VQ>?	M2n0N\|EhcA>?	MYDEUXNQ	MmjlVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN?	M1PrcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki0NFk6Lz5zN{[4OFA6QTxxYU6=
U937	MoX2SpVv[3Srb36gRZN{[Xl?	M3Ll[FEh\|ryP	NWTlS5hTOSCq	MnzBSG1UVw>?	MnnJVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>	MnHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OESwPVkoRjF5Nki0NFk6RC:jPh?=
murine mast cell	NED2Um9HfW6ldHnvckBCe3OjeR?=	NYm5eGl1OSEQvF2=	MlTFNlQhcA>?	M4ewdWROW09?	NHjje\|RKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?=	MnTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OESwPVkoRjF5Nki0NFk6RC:jPh?=
FDC-P1	NHLIXYxHfW6ldHnvckBie3OjeR?=		M3;pUVQ5KGi{cx?=		MliwTWM2OCB;IECuNFA4PCEQvF2=	NFfLVlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1OlY5QSd-MkCxOVY3QDl:L3G+
K562	MnXtR5l1d3SxeHnjbZR6KGG\|c3H5		Mk\IO\|IhcHK\|		NF;RNJhKSzVyIE2gNVIvQDNizszN	NGO2[JQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxO\|g4Pyd-MkKyNVc5Pzd:L3G+
U937	Mn:zR5l1d3SxeHnjbZR6KGG\|c3H5		NHvTeJI4OiCqcoO=		NEDifpdKSzVyIE2gNVMvPjNizszN	NWPDRWpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVc5PzdpPkKyNlE4QDd5PD;hQi=>
Sf21	M1ztd2Z2dmO2aX;uJIF{e2G7		MmLMOUBucW6\|		MVfJR\|UxKD1iMUCg{txO	M2LQblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xOlgyLz5{Mkm2NVY5OTxxYU6=
Ba/F3	M4PrUmZ2dmO2aX;uJIF{e2G7		NFjSZY4yKGi{		M4SwbWlvcGmkaYTpc44hd2ZiQnPyMWFjdCCWM{G1TUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV3RCXDVibHX2[Ywh[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEiwOkc,OjN4MEC4NFY9N2F-
Ba/F3	NUn0fWx[TnWwY4Tpc44h[XO\|YYm=		M{W5WFEhcHJ?		M4XaOGlvcGmkaYTpc44hd2ZiQnPyMWFjdCCWM{G1TUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgR5JsVCCuZY\lcEBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEiwOkc,OjN4MEC4NFY9N2F-
Ba/F3	M1nkVGZ2dmO2aX;uJIF{e2G7		NUO1W4dKOSCqch?=		M2m5N2lvcGmkaYTpc44hd2ZiQnPyMWFjdCCWM{G1TUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDwbI9{eGixconsZZRqd25idILhcpNn\WO2ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMEiwOkc,OjN4MEC4NFY9N2F-
Sf9	M2XIOmZ2dmO2aX;uJIF{e2G7		MkfBNVUhfG9iMkCgcYlvew>?		NX3nPGNmUUN3MDC9JFE{NjFizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl3NkGwNUc,OjN7NU[xNFE9N2F-
Sf9	MknTSpVv[3Srb36gZZN{[Xl?		NWfYWlBVOjBibXnudy=>		MmLlTWM2OCB;IEK3MlMh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl3NkGwNUc,OjN7NU[xNFE9N2F-
HMC-1.2	MmXSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NX\QSXZ3UUN3MDC9JFAvQDJizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNESwPUc,OjVyMES0NFk9N2F-
RXF 393NL	NWf6SYFMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHjjZYI1KGSjeYO=		NIjxUVhIUTVyIE2gNE4xOjF5IN88US=>	NGnJZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
LXFA 983L	Mmn6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXG0JIRigXN?		M1PlWmdKPTBiPTCwMlA2PjVizszN	M1ruU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
PRXF DU145	NUL6XoJISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGP1UW81KGSjeYO=		M1fRUWdKPTBiPTCwMlA3OjNizszN	M2jIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
PAXF 1657L	MlPaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVq0JIRigXN?		M2XjVmdKPTBiPTCwMlEzOSEQvF2=	NXzkOnlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
GXF251L	NFvP[plCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MX60JIRigXN?		M1TwZmdKPTBiPTCyMlI2KM7:TR?=	NUTmVJNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
CXF 1103L	NVy3UG5jSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mm\BOEBl[Xm\|		MlWyS2k2OCB;IESuN\|Yh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5NkG5OUc,OjVyN{[xPVU9N2F-
SH-SY5Y	MXjBdI9xfG:\|aYOgZZN{[Xl?	NVLHR3dbOC5zIIXN	M2PmPFI1KGi{cx?=		MYDJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFOKLWPZOXkh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJIh6eG:maYDsc4llKGOnbHzzJIF1KDBwMTD1UUBi\nSncjCyOEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCleYTv[ox2d3KrbXX0dpk>	MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2Nkm3O\|EoRjJ3NE[5O\|cyRC:jPh?=
ECRF24	NHzOfmVEgXSxdH;4bYNqfHliYYPzZZk>		M3vDTlczKGi{cx?=		NHvme21KSzVyIE2gOU44KM7:TR?=	NFzDPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixOVE2Oid-MkW4NVUyPTJ:L3G+
A2780	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		M3:3blczKGi{cx?=		MoHETWM2OCB;IEiuO{DPxE1?	NIXTO5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixOVE2Oid-MkW4NVUyPTJ:L3G+
HEK293	MYPDfZRwfG:6aXPpeJkh[XO\|YYm=		M133[FczKGi{cx?=		NXXh[G9{UUN3MDC9JFE1NjNizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzNUG1Nkc,OjV6MUWxOVI9N2F-
MDA-MB-231	NETnb4REgXSxdH;4bYNqfHliYYPzZZk>		M4rFelczKGi{cx?=		M1PlXGlEPTBiPTCwMlE4QCEQvF2=	NYTxVoRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{OTdpPkK1PFM2OzF5PD;hQi=>
MDA-MB-231	NEDmRphCdnSraX72ZZNqfmViYYPzZZk>	NHvVO2ExNjFidV2=	M2G1[\|I1KGi{cx?=		MUnBcpRqcW64YYPpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFAvOSC3TTDh[pRmeiB{NDDodpMh[nlidILhcpN4\WyuIHHzd4F6	MkTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	NI\Xb5FE\WyuIHP5Z4xmKGG\|c3H5	MXSwMlMhfU1?	NIXuUXEzPCC2bzC0PEBpenN?		NULLcoNlS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzBxR{GgdIhie2ViYYSgNE4{KHWPIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYO=	NFKyWHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	Ml3BSpVv[3Srb36gZZN{[Xl?	MnTrQlAvODNidV2=	NELkZXMzOCCqcoO=		MW\Jcohq[mm2aX;uJI9nKFO{YzDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCIQVugdIhwe3Cqb4L5cIF1cW:wIHH0JF4xNjB\|IIXNJIFnfGW{IEKwJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M4ru[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	NEDUO\|hCdnSrbXnndoF1d3K7IHHzd4F6	M{TBSFAvODNidH:gNE4{KHWP	M3;0NFIxKGi{cx?=		NYDEOJg5SW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wN{B1dyByLkOgeW0h[W[2ZYKgNlAhcHK\|IHL5JJdwfW6mIHjlZYxqdmdiYYPzZZk>	MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	MXzGeY5kfGmxbjDhd5NigQ>?	MkHYNE4xODFidH:gNUB2VQ>?	M{jxfFIxKGi{cx?=		M1vtSWlvcGmkaYTpc44hd2ZiU4LjJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFAvODBzIITvJFEhfU1iYX\0[ZIhOjBiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NFL6VmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	MorxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MoDMQlAvODFidV2=	M1jIeFEzKGSjeYO=		MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBkd2yxbomg[o9zdWG2aX;uJIF1KD5yLkCxJJVOKGGodHXyJFEzKGSjeYOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnetZoF{\WRiYYPzZZk>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	MmfBRY51cXS3bX;yJIF{e2G7	MonNOFAhdWdxa3ev[IF6	MoLqNVgh\GG7cx?=		NG\KN2VCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IIjlco9oemGodHXkJIlvKFOFSVSgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgOFAhdWdxa3ev[IF6KGGmbXnubZN1\XKnZDDmc5IhOThiZHH5d{Bu\WG\|dYLl[EBmfmW{eTCzJIRigXNiZIXybY5oKGOxbYDveY5lKGSxc3nu[y=>	M4ftZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	NF3G[WJEgXSxdH;4bYNqfHliYYPzZZk>		M1fuUVQ5KGi{cx?=		NX\SOmk6UUN3MDC9JFEvOTJizszN	M4ft[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEm5N\|MzLz5{NUi5PVM{OjxxYU6=
MCF7	M3K5UmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NInST2o1QCCqcoO=		M2fydmlEPTBiPTC4MlA2KM7:TR?=	NX7XUYN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PVk{OzJpPkK1PFk6OzN{PD;hQi=>
HCC366	NXnlNZlRSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWHCdY04PzJiaILz		MmHUTWM2OCB;IECuNFI6KM7:TR?=	NGXmOIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG5NVM3QSd-Mk[xPVE{Pjl:L3G+
NCI-H2286	NGTCZZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NITRcJI4OiCqcoO=		NWn3V4tzUUN3MDC9JFAvODN{IN88US=>	NHTwNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG5NVM3QSd-Mk[xPVE{Pjl:L3G+
K562	M3TyN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUe3NkBpenN?		NI\pd4dKSzVyIE2gNE4xODFizszN	MlHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUWxN\|YoRjJ4MUm1NVM3RC:jPh?=
K562	M1vmU2N6fG:2b4jpZ4l1gSCjc4PhfS=>				M{XHdGlEPTBiPTCwMlA5KM7:TR?=	Mo\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NkS1NFMoRjJ4Mk[0OVA{RC:jPh?=
IR-K562	MlHwR5l1d3SxeHnjbZR6KGG\|c3H5				NX61W2NOUUN3MDC9JFEvQSEQvF2=	NXq1eW9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlQ2ODNpPkK2NlY1PTB\|PD;hQi=>
THP1	Mo\UR5l1d3SxeHnjbZR6KGG\|c3H5				MkHiTWM2OCB;IE[g{txO	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NkS1NFMoRjJ4Mk[0OVA{RC:jPh?=
HEK293	MX;DfZRwfG:6aXPpeJkh[XO\|YYm=				MnT1R2M2OCB;IEG2JO69VQ>?	NILMeGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2OFUxOyd-Mk[yOlQ2ODN:L3G+
K562	NXLtOVIxS3m2b4TvfIlkcXS7IHHzd4F6		Mn\wOFghcHK\|		MVjJR\|UxKD1iMD60OUDPxE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3MUe3Nkc,OjZ2NUG3O\|I9N2F-
K562	Mn\kRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGW5NGY4OiCqcoO=		NH\r[o9IUTVyIE2gNE4xODB\|IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NUnOTGRMTnWwY4Tpc44h[XO\|YYm=		MnPHO\|IhcHK\|		MoHWS2k2OCB;IECuNFAxOyEQvF2=	NISyOmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	NWf5NGRjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmS0O\|IhcHK\|		MkDTS2k2OCB;IECuNFAxOyEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
MEG01	NGnJ[ppCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MU[3NkBpenN?		NXvvUZBPT0l3MDC9JFAvODByMzFOwG0>	NGHOVGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	MWjGeY5kfGmxbjDhd5NigQ>?		MnzsO\|IhcHK\|		MWHHTVUxKD1iMD6wNFEh\|ryP	NWnrd4dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	M2\ESmZ2dmO2aX;uJIF{e2G7		M2P5dVczKGi{cx?=		MofnS2k2OCB;IECuNFAyKM7:TR?=	MmnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	NH6zNWpHfW6ldHnvckBie3OjeR?=		MVO3NkBpenN?		NVLYeoJ4T0l3MDC9JFAvODBzIN88US=>	NXzjOm13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	MkXKSpVv[3Srb36gZZN{[Xl?		MYq3NkBpenN?		NFf3U3RIUTVyIE2gNE4xODNizszN	M3vrfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NWj1ZoI5TnWwY4Tpc44h[XO\|YYm=		NWHFPW83PzJiaILz		NELlVZJIUTVyIE2gNE4xODNizszN	M1K5ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NEDnNlBHfW6ldHnvckBie3OjeR?=		MonrO\|IhcHK\|		M1G0WWdKPTBiPTCwMlAxOyEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MoPiSpVv[3Srb36gZZN{[Xl?		NVq2[49IPzJiaILz		MXvHTVUxKD1iMD6wNFMh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NFryZnZHfW6ldHnvckBie3OjeR?=		Mn\iO\|IhcHK\|		MXPHTVUxKD1iMD6wNFQh\|ryP	NYDXUZBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	MnHESpVv[3Srb36gZZN{[Xl?		MkfuO\|IhcHK\|		NGrhbWdIUTVyIE2gNE4xODRizszN	M{HzNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NFOybndHfW6ldHnvckBie3OjeR?=		NXP3WplKPzJiaILz		NV;yO3dpT0l3MDC9JFAvODB3IN88US=>	MkPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M{eySWZ2dmO2aX;uJIF{e2G7		MVy3NkBpenN?		Mlf5S2k2OCB;IECuNFA5KM7:TR?=	MoroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MX;GeY5kfGmxbjDhd5NigQ>?		MXS3NkBpenN?		MkH6S2k2OCB;IECuNFA5KM7:TR?=	M4[zcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	MofLSpVv[3Srb36gZZN{[Xl?		M3jMbVczKGi{cx?=		MVrHTVUxKD1iMD6wNUDPxE1?	Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MlqxSpVv[3Srb36gZZN{[Xl?		MVe3NkBpenN?		MVHHTVUxKD1iMD6wNVQh\|ryP	NF\YNZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NHzsdFhHfW6ldHnvckBie3OjeR?=		M1\mSVczKGi{cx?=		MoLDS2k2OCB;IECuNFE1KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NEjaN2JHfW6ldHnvckBie3OjeR?=		MX63NkBpenN?		NHPnOldIUTVyIE2gNE4xOTdizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NGHUSGhHfW6ldHnvckBie3OjeR?=		NEDZRlI4OiCqcoO=		M3;BNWdKPTBiPTCwMlA{QSEQvF2=	M4L2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
CHL	M4T4O2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGflN484OiCqcoO=		NWntWog4T0l3MDC9JFAvOjdizszN	NYTucGY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
MOLM14	MnjWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{fPXFczKGi{cx?=		MoXVS2k2OCB;IEKuN{DPxE1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	M3nHdmZ2dmO2aX;uJIF{e2G7		MlzVO\|IhcHK\|		NVnlTVVbT0l3MDC9JFMh\|ryP	NYT5OGtqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	M{GzfGZ2dmO2aX;uJIF{e2G7		MlfaO\|IhcHK\|		MVfHTVUxKD1iMzFOwG0>	MnnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
MV4-11	MmnmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYS3NkBpenN?		NXjEO\|NmT0l3MDC9JFMvPiEQvF2=	M{XzWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
HEL	M1S5ZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1H0WFczKGi{cx?=		MULHTVUxKD1iNT6zJO69VQ>?	NHjXclc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	M3vNPWZ2dmO2aX;uJIF{e2G7		NXnRVZZzPzJiaILz		MV;HTVUxKD1iOT65OEDPxE1?	NHrsdmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	NU\iPXRITnWwY4Tpc44h[XO\|YYm=	M{SxfFAvOSC3TR?=	NHToUIwyKGi{		MkfqTY5pcWKrdHnvckBw\iCEQ2KvRWJNKGmwIHj1cYFvKEuXOEGyJINmdGy\|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGNzc0xicHjvd5Bpd3K7bHH0bY9vKGG2IGSyNFche2m2ZTDheEAxNjFidV2gZYZ1\XJiMTDodkBjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
KU812	MX3GeY5kfGmxbjDhd5NigQ>?	MVGwMlEhfU1?	NEDnTJQyKGi{		M4nIUGlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCNVUixNkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
MEG01	MXnGeY5kfGmxbjDhd5NigQ>?	MnTTNE4yKHWP	MUOxJIhz		NV;DWmFIUW6qaXLpeIlwdiCxZjDCR3IwSUKOIHnuJIh2dWGwIF3FS\|AyKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEO{a1ygdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODdic3n0[UBifCByLkGgeW0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	NFy2S2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
MEG01	MlfBSpVv[3Srb36gZZN{[Xl?	NVzwcodNOC5zIIXN	NF73OIkyKGi{		M2nWdWlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCPRVewNUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	NVXPOo05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
K562	MlLwSpVv[3Srb36gZZN{[Xl?	NVLrRWNIOC5zIIXN	NW\1cYZoOSCqch?=		NHPZPVFKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS{W2NkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
K562	MYjGeY5kfGmxbjDhd5NigQ>?	NVPSNXBlOC5zIIXN	MVOxJIhz		NWq5bIhRUW6qaXLpeIlwdiCxZjDCR3IwSUKOIHnuJIh2dWGwIFu1OlIh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS3KtTDDwbI9{eGixconsZZRqd25iYYSgWFIxPyC\|aYTlJIF1KDBwMTD1UUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
K562	MmPNR5l1d3SxeHnjbZR6KGG\|c3H5		NFWyVYk4OiCqcoO=		NGX4OWlKSzVyIE2gNE4xODB{NTFOwG0>	NF;VfYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkixOFg6OCd-Mk[4NVQ5QTB:L3G+
BA/F3	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		NYXiUoNoPzJiaILz		NETZfGVKSzVyIE2gNE4xQSEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjhzNEi5NEc,OjZ6MUS4PVA9N2F-
BAF3	MV3GeY5kfGmxbjDhd5NigQ>?		MmXrO\|IhcHK\|		NWrv[I15TUN3MDC9JFAvODByMESg{txO	M4P4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
BAF3	M3rtZWZ2dmO2aX;uJIF{e2G7		M{nkPVczKGi{cx?=		M3ixRWVEPTBiPTCwMlAxODB2IN88US=>	M13DVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
BxPC3	NILTbHBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV[5N2cxPzJiaILz		MlvzSWM2OCB;IECuNFM{KM7:TR?=	NIfkRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
MDA-MB-231	NXTabllVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWi3NkBpenN?		MWHFR\|UxKD1iMD6wOFQh\|ryP	M4XURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
Caki2	NILYOplCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWDyc3ZEPzJiaILz		M3;kVWVEPTBiPTCwMlA2PSEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
NCI-H1975	M2PoXmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2OwWVczKGi{cx?=		NFfH[WtGSzVyIE2gNE4yPzNizszN	NXr2epBrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVA5OTBpPkK3NFExQDFyPD;hQi=>
PC3	NGfoSHNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2[5dVczKGi{cx?=		NW\IVJpYTUN3MDC9JFAvOjN{IN88US=>	M1jkS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
insect	NWjSZYpuTnWwY4Tpc44h[XO\|YYm=		NXLweXJzOjBibXnudy=>		MlnhTWM2OCB;IECuNFAxPSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
MDA-MB-231	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NX63SlZWPSCmYYnz		MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSCScnXzeI9DdHWnIHHzd4F6	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
MDA-MB-231	NGLTcZlHfW6ldHnvckBie3OjeR?=	MoDPN{B1dyBzMECgcm0>	NYXWPGFVOS53IHjydy=>		NFjxOFFKdmirYnn0bY9vKG:oIGPSR{BxcG:\|cHjvdplt[XSrb36gZZQhfHm{b4PpcoUhPDF4IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgN{B1dyBzMECgcm0heHKnaX7jeYJifGWmIH\vdkAyNjViaILzJIZwdGyxd3XkJIJ6KHOncoXtJJN1cW23bHH0bY9vKG[xcjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NIHHUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
MDA-MB-231	MXPGeY5kfGmxbjDhd5NigQ>?	MoTrN{B1dyBzMECgcm0>	MUCxMlUhcHK\|		M4G0PWlvcGmkaYTpc44hd2ZiRlHLJJBpd3OyaH;yfYxifGmxbjDheEB1gXKxc3nu[UA5PjFiaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCzJJRwKDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFEvPSCqcoOg[o9tdG:5ZXSgZpkhe2W{dX2gd5RqdXWuYYTpc44h\m:{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	Mnf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MDA-MB-231	MnvSRY51cW2rZ4LheI9zgSCjc4PhfS=>	Mn3rNVAhdk1?	MmjOOkBpenN?		Mk\VRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuIH3veIltcXS7IHH0JFExKG6PIHH0JFYhcHK\|IHL5JI1q[3Kxc3PvdJkh[mG\|ZXSgd4Nz[XSlaD33c5Vv\CClZXzsJI1q\3KjdHnvckBie3OjeR?=	MnHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MCF7	Mm\ERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MkTsNE4xOyC2bzCzNFAhfU1?	NWXLdXlwPSCmYYnz		MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDBwMEOgeI8hOzByIIXNJIFnfGW{IEWg[IF6eyCkeTDQdoV{fG:EbIXlJIF{e2G7	M{exWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG1PFM2Lz5{N{GxOVg{PTxxYU6=
HCT116	NIDLS5JEgXSxdH;4bYNqfHliYYPzZZk>		MoPrPVYhcHK\|		MVfJR\|UxKD1iNT6yN{DPxE1?	M{nV[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY1Lz5{N{G1OVQ3PDxxYU6=
A549	M2rxV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M1rFUlk3KGi{cx?=		MVrJR\|UxKD1iOD6zO{DPxE1?	M3vqSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY1Lz5{N{G1OVQ3PDxxYU6=
U937	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=		MkLjPVYhcHK\|		NHTodFJKSzVyIE2gNVAvOjNizszN	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNUW0OlQoRjJ5MUW1OFY1RC:jPh?=
K562	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=		M4jse\|k3KGi{cx?=		M2TqR2lEPTBiPTCxNU46PSEQvF2=	NIHOblA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G1OVQ3PCd-MkexOVU1PjR:L3G+
K562	MnftR5l1d3SxeHnjbZR6KGG\|c3H5				NWL1To9uS0N3MDC9JFAvOjVizszN	NYHmPZBCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0O\|Q6OThpPkK3OFc1QTF6PD;hQi=>
K562	NEXXS4JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NEfXenNIUTVyIE2gNE4xODFizszN	NFTaNWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzOVUzPid-Mki0N\|U2OjZ:L3G+
K562	NHXTUZRHfW6ldHnvckBie3OjeR?=				MnjHTWM2OCB;IECuNFAxODZ7IN88US=>	M2HSUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{m1PVc{Lz5{OUO5OVk4OzxxYU6=
HL60	MUXGeY5kfGmxbjDhd5NigQ>?				NEjvW41KSzVyIE2gNE4xODBzMTFOwG0>	MorUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|OUW5O\|MoRjJ7M{m1PVc{RC:jPh?=
KG1a	M1v1OWZ2dmO2aX;uJIF{e2G7				M4HxV2lEPTBiPTC4Mlk5KM7:TR?=	NGXyb5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
B16-BL6	NV\BcGVnTnWwY4Tpc44h[XO\|YYm=	MmjyPE4yOyC3TR?=	MY[yOEB1dyB2ODDodpM>		NUnVNYpCUW6qaXLpeIlwdiCxZjDj[YxtKG2rZ4LheIlwdiCxZjDtc5V{\SCEMU[tRmw3KGOnbHzzJIF1KDhwMUOgeW0hcW6ldXLheIVlKG[xcjCyOEB1dyB2ODDodpMh[nliY3XscEB4d3WwZDDzZ5JifGOqIHHzd4F6	NEPDc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
MCF7	NH23VIRHfW6ldHnvckBie3OjeR?=	MX[3MlUhfU1?	MXqxNEBl[Xm\|		MVjJcohq[mm2aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44hcW5iaIXtZY4hVUOINzDj[YxteyCjdDC3MlUhfU1iaX7jeYJifGWmIH\vdkAyOCCmYYnzJIJ6KGO{eYP0ZYwhfmmxbHX0JJN1[WmwaX7nJIJie2WmIIDsZZRmKGOub37pcochfGW\|dB?=	M4naVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{m1PVc{Lz5{OUO5OVk4OzxxYU6=
U-2 OS	NWOxXHlPeUiWUzDhd5NigQ>?				M3W4bZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCXLUKgU3Mh[2WubIO=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	MUPxTHRUKGG\|c3H5				NGHVR5pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MkPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	M4r1SZFJXFNiYYPzZZk>				MofzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M{LwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	M{HxTpFJXFNiYYPzZZk>				NUjVbGtoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	NUn3Wm5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NFPCRnJyUFSVIHHzd4F6				MnTMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	M1vC[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NH\OTm9yUFSVIHHzd4F6				NVO5OphZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NFv4eJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MWjxTHRUKGG\|c3H5				NX7sVoMxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M{HjN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MX\xTHRUKGG\|c3H5				NYP1O5hXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NWHZZ4tZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M{XXW5FJXFNiYYPzZZk>				M17SbZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	NYP6bWo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	MmjIdWhVWyCjc4PhfS=>				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	MV\xTHRUKGG\|c3H5				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	MkHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NVHiPFdKeUiWUzDhd5NigQ>?				NWn0O4NyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MoLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M1\u[ZFJXFNiYYPzZZk>				NF7ZXnhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NXH3TGRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NYrnbmtweUiWUzDhd5NigQ>?				NULRNoFjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NUX3XotHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	M2HzT5FJXFNiYYPzZZk>				M1[1PJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	NVjkd4dERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	Mm\wdWhVWyCjc4PhfS=>				MkT5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	MlS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HEK293	M3LpO2Z2dmO2aX;uJIF{e2G7		M4LMT\|EhcHJ?		MmnwT4khRSByLkCwNFUh\|ryP	NXjQOI45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl\|PD;hQi=>
HEK293	MnzNSpVv[3Srb36gZZN{[Xl?		NF\LRWwyKGi{		M4HjPGlEPTBiPTCwMlAxPiEQvF2=	NYLNO3hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl\|PD;hQi=>
Ba/F3	NX\1O4t3TnWwY4Tpc44h[XO\|YYm=		NX7JW5JVPDhiaILz		NUK5cpI1T0l3MDC9JFAvODByMkGg{txO	NWC1VGdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	MnzkSpVv[3Srb36gZZN{[Xl?		NXfOOYdoPDhiaILz		NUTzfJFQT0l3MDC9JFAvODByMkWg{txO	MoLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	NVvBNXV2TnWwY4Tpc44h[XO\|YYm=		MUe0PEBpenN?		M1zRWmdKPTBiPTCwMlAxODJ7IN88US=>	M{\O[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	NELmXXNHfW6ldHnvckBie3OjeR?=		MnfKOFghcHK\|		MmH2S2k2OCB;IECuNFAxOyEQvF2=	M3XVOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	NULNWlBnTnWwY4Tpc44h[XO\|YYm=		NFq5RVU1QCCqcoO=		NIn2TpVIUTVyIE2gNE4xODB\|MzFOwG0>	MoTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	M4ewXGZ2dmO2aX;uJIF{e2G7		MnXIOFghcHK\|		MnvWS2k2OCB;IECuNFAxPDJizszN	NFW4UYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	MkT0SpVv[3Srb36gZZN{[Xl?		NHf3T4Q1QCCqcoO=		M3;BOmdKPTBiPTCwMlAxODd5IN88US=>	NGWzT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	NGO2XmNHfW6ldHnvckBie3OjeR?=		NFjienU1QCCqcoO=		MVfHTVUxKD1iMD6wNFA6QCEQvF2=	MonYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	NVTrZo5mTnWwY4Tpc44h[XO\|YYm=		MnjFOFghcHK\|		MYXHTVUxKD1iMD6wNFE1PCEQvF2=	NI\DO\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	MlGxSpVv[3Srb36gZZN{[Xl?		MnLTOFghcHK\|		MVnHTVUxKD1iMj61OlIh\|ryP	MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Vero	NX\UR\|RyeUiWUzDhd5NigQ>?				NFn6ZVVX\XKxIHPlcIx{KH[rYXLpcIl1gSCzSGTTJIZweiCcaXvhJJZqenW\|IHnubIljcXSxcoO=	M{jwNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN\|MkK5OVQ2Lz5\|M{KyPVU1PTxxYU6=
HepG2	Mlv0dWhVWyCjc4PhfS=>				NGT0VpNJ\XCJMjDj[YxteyC4aXHibYxqfHlicVjUV{Bnd3JiWnnrZUB3cXK3czDpcohq[mm2b4Lz	M1zsUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN\|MkK5OVQ2Lz5\|M{KyPVU1PTxxYU6=
BV-173	M3Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX3Sm1TUUN3ME2wMlAxODByMEGwPUDPxE1?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
K-562	NYLLWIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[xZlBSUUN3ME2wMlAxODByMEK2OkDPxE1?	NFuy[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BL-70	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzITWM2OD1yLkCwNFAxODh{MjFOwG0>	Mn21QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
EM-2	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3GRllKSzVyPUCuNFAxODBzMEig{txO	M3PvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LAMA-84	NVjNSpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG1TWM2OD1yLkCwNFAxOzJzIN88US=>	MnzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MEG-01	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnaTWM2OD1yLkCwNFAxQThizszN	M1TO[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EoL-1-cell	NFXhPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTBwMECwNFE{OSEQvF2=	MmPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CTV-1	M4PaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvITWM2OD1yLkCwNFA1ODRizszN	NFrnd\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-15	NGDmNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fvV2lEPTB;MD6wNFU5QSEQvF2=	MofuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NOS-1	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTZd3RlUUN3ME2wMlAxPjF\|IN88US=>	M1\hR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
D-336MG	NFP2bFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwMEC2N{DPxE1?	Ml7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB1047-RCC	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTBwMEC5PFkh\|ryP	NI\6[\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB996-RCC	M33ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTBwMEC5PVEh\|ryP	NWruTnlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW982	M4LrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTBwMEGxNVUh\|ryP	NIrtVm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TK10	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTBwMEGxO\|Qh\|ryP	MnzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A704	NEj2WWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HBZmlEPTB;MD6wNVQ6OSEQvF2=	NIjT[2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-8	NWXSfHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrSTWM2OD1yLkCxOVc3KM7:TR?=	NIjlWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
DOHH-2	NYrtOmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\SelZYUUN3ME2wMlAyPzF7IN88US=>	NUKzVXpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HOP-62	NH3LN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDkTWM2OD1yLkCxPFM1KM7:TR?=	NYPW[pQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-12	NFPJVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmW0TWM2OD1yLkCxPFYyKM7:TR?=	NHTUTmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KGN	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTBwMEG5OFIh\|ryP	M3nGVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1648	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rDNWlEPTB;MD6wNlAyOSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
OS-RC-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEO1emFKSzVyPUCuNFIxOyEQvF2=	M3v2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GB-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwMEKxOVch\|ryP	NFnMPHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
RXF393	M3TE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe4N3JKSzVyPUCuNFI{PTdizszN	MnfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LC-2-ad	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj4e2pKSzVyPUCuNFI2QDZizszN	MnewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KS-1	M4nKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zCR2lEPTB;MD6wNlc{KM7:TR?=	Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ETK-1	NET2fWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMEK4N\|Ih\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SW954	NVjI[4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3tTWM2OD1yLkCyPVI4KM7:TR?=	NWX5Um55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
Becker	NWf4O4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwMEOwNFMh\|ryP	NWjJdYdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MZ1-PC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTLcWlyUUN3ME2wMlA{OTF7IN88US=>	NUDFeZNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ES6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE[wfFhKSzVyPUCuNFMyQTNizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KURAMOCHI	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DiVWlEPTB;MD6wN\|Q5PyEQvF2=	NFzQc5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CGTH-W-1	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEftfpJKSzVyPUCuNFM2PDhizszN	NIfnOWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NWnlPYVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDVO4p7UUN3ME2wMlA{QTB{IN88US=>	NHraPJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LXF-289	NWPDVmoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVy3fVFUUUN3ME2wMlA{QTV4IN88US=>	NWLVfYY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MPP-89	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnWTWM2OD1yLkC0NFQ6KM7:TR?=	NV\wOWNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW872	M{T5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17xN2lEPTB;MD6wOFE3OSEQvF2=	NUDrWXR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SNB75	M3K2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKyXYxKSzVyPUCuNFQ1OzVizszN	NWXHSJp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
PSN1	NWTYWXllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;PTWM2OD1yLkC0OFc1KM7:TR?=	NE\3OFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB831-BLC	NUPQUW9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzGT3RKSzVyPUCuNFQ3ODlizszN	NYfidmdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MFH-ino	M3O0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVztWGRZUUN3ME2wMlA1PzJ2IN88US=>	NVPDeGFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TGBC24TKB	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTBwMES3OlEh\|ryP	MlHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A388	NHPE[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2H6d2lEPTB;MD6wOVA6PSEQvF2=	NHPGWnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BB30-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwMEW0N\|ch\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
GI-ME-N	NHHPfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHxcppYUUN3ME2wMlA3OTF6IN88US=>	NECydYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TGBC1TKB	NIHwW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPQTWM2OD1yLkC2NVY1KM7:TR?=	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-10	NFXLOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFG2XJFKSzVyPUCuNFY{PTdizszN	NXjTTHdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
A498	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTBwMEeyPFQh\|ryP	NVXieJhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-11	M1mxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkOzTWM2OD1yLkC3PFU5KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BB65-RCC	M37QPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzWTWM2OD1yLkC4NlI4KM7:TR?=	M1ewflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
C2BBe1	M3r0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PnWWlEPTB;MD6wPFMxQCEQvF2=	NXvPSo5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H747	NWfKU3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XINWlEPTB;MD6wPFM3OiEQvF2=	NX\HWFN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
IST-MES1	NUnu[GhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMEi1OVIh\|ryP	M4PUU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KALS-1	NGnS[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTPb5NKSzVyPUCuNFk1QSEQvF2=	M2nkRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GCIY	NGC1VXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrWTWM2OD1yLkC5OlU3KM7:TR?=	NEDUcmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
RL95-2	NWjlWmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTBwMUCzPEDPxE1?	M3PrblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TE-1	NX71Z4NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMUC1OEDPxE1?	NES2Vm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H1355	M1PXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkCzTWM2OD1yLkGxNFI5KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SW962	M2\peGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3te\|hSUUN3ME2wMlEyOjl{IN88US=>	Ml\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KLE	M{nFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\OPHlKSzVyPUCuNVE{OTdizszN	Ml3ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MC116	M4PFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fP[mlEPTB;MD6xNVQyKM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NMC-G1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGK3W\|hKSzVyPUCuNVE3ODZizszN	M2fnSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KU812	M3LoU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLyUYdKSzVyPUCuNVE5QDNizszN	NIfrWo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COLO-829	NFr5NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorSTWM2OD1yLkGyNlE{KM7:TR?=	NH75Umg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NGn5fGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i3TmlEPTB;MD6xNlI5OyEQvF2=	MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
IST-MEL1	MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33Le2lEPTB;MD6xN\|Q2KM7:TR?=	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MLMA	M1zGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2iyZ2lEPTB;MD6xOFA{OiEQvF2=	Mmi1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LS-123	NHjqNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTBwMUSwOlQh\|ryP	MoXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB2518-MEL	M2DifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn0TWM2OD1yLkG0NVYzKM7:TR?=	MoHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB69	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMUS0N\|Yh\|ryP	NVTZdWdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
8-MG-BA	NUfscWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPhbFlMUUN3ME2wMlE2PDV6IN88US=>	NHnUSGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
K5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMU[0PFkh\|ryP	MnjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KINGS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkS5TWM2OD1yLkG2OlY3KM7:TR?=	NEnBNZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SF268	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zCNWlEPTB;MD6xO\|QxPCEQvF2=	NWDs[GZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
PF-382	M3\CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjKTWM2OD1yLkG3Olc5KM7:TR?=	NYnZ[4tpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SH-4	M3HtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTBwMUi0NVMh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NALM-6	NE\pXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkmwTWM2OD1yLkG5Nlk2KM7:TR?=	M2qzVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
CP66-MEL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfzOWZKSzVyPUCuNVk2OzFizszN	NIrRUWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
697	NU\rUZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXZTWM2OD1yLkG5PVg4KM7:TR?=	NGrqPII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CP67-MEL	NV\5c5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrtRXlKSzVyPUCuNlA1QDhizszN	MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DSH1	NEm0WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL1OYFKSzVyPUCuNlQxODFizszN	M4KxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HCE-4	NU\ZPIJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTBwMk[0N\|kh\|ryP	NXmxVYFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MZ2-MEL	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1T6NmlEPTB;MD6yPFU{PyEQvF2=	NUmwdI1uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BL-41	NV\DTldRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILL[lhKSzVyPUCuNlkyOjNizszN	M1Pre\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HUTU-80	M1H5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHaOohEUUN3ME2wMlMyPDJizszN	MnTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LOXIMVI	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP0ZXg6UUN3ME2wMlMyPTB\|IN88US=>	NIfvOYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
no-10	NXH4OZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;IVmlEPTB;MD6zNVk{OSEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KARPAS-422	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfaTWM2OD1yLkOzPVk4KM7:TR?=	NF;zOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SW684	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\yTWM2OD1yLkO0PVgh\|ryP	NX;lXlM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SF126	NYLDTJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHZVoRKSzVyPUCuN\|U1OSEQvF2=	NXXl[ohoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
D-263MG	M{jlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjmTWM2OD1yLkO2NlI1KM7:TR?=	M1fYUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
OVCAR-4	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvuOXVKSzVyPUCuN\|c1OzNizszN	NIX6fVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BB49-HNC	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkX2TWM2OD1yLkO4OVk6KM7:TR?=	MlzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ONS-76	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLKeXJJUUN3ME2wMlQzQTVzIN88US=>	NEDheoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MZ7-mel	M3nhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLnTWM2OD1yLkS3PVEyKM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RCC10RGB	M1fNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7jTWM2OD1yLkS5NVEh\|ryP	NGn4R4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BOKU	NX21cJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG2TWM2OD1yLkS5NVM{KM7:TR?=	M2\vfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
no-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXLUpN4UUN3ME2wMlUxOjJ6IN88US=>	NUW5T3FURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
IST-SL2	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTBwNUCzNFIh\|ryP	M4DRbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
RKO	NXPse2hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwNUK5OlYh\|ryP	NWTIW244RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HT-144	M2X0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTCNIMxUUN3ME2wMlU{PjB7IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H446	M1zaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{e2d2lEPTB;MD62Nlc3KM7:TR?=	M3zaOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
QIMR-WIL	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwN{C2Nlkh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MHH-PREB-1	NInlOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnGPI1KSzVyPUCuO\|Q1PjlizszN	M4j5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EW-16	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrBS3JKSzVyPUCuO\|YyPzhizszN	M4qzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EW-24	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3JZYtKUUN3ME2wMlc5OTZ3IN88US=>	NHfKNWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB373-MEL-D	M2ToV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjCcXdKSzVyPUCuPFI2ODhizszN	NETsXog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-9	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwOEe1N\|Ih\|ryP	M{H5cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A3-KAW	NHPxbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnDco5UUUN3ME2wMlk5PDV{IN88US=>	NH;CdGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A101D	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn70TWM2OD1zLkCzNFQ{KM7:TR?=	NInhOlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OCUB-M	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXXTWM2OD1zLkC0OFEzKM7:TR?=	MlGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ES4	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHPSnR3UUN3ME2xMlA2OTR3IN88US=>	NFjsWZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-6	NGLVcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwMkGyNlYh\|ryP	NU\oZ\|QxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
D-502MG	NHm1PVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PQUmlEPTB;MT6yN\|M4PiEQvF2=	NWXVSmZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KNS-42	NHrCXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HJN2lEPTB;MT6yOFQyOiEQvF2=	NIDxZ2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SNU-C2B	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjjN\|VtUUN3ME2xMlMxPTh7IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H1838	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDUb4FIUUN3ME2xMlMxPzN\|IN88US=>	MonhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NKM-1	NVrVbmRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfrZlFkUUN3ME2xMlMxQDV7IN88US=>	M3fBSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GI-1	Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfoXWl[UUN3ME2xMlM3OjJizszN	NYnDfXhIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NB5	MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXrWZJMUUN3ME2xMlM6QDJ5IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
CAS-1	NVrYOmVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHQblVKSzVyPUGuOFA6QTJizszN	NWfXepR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HCE-T	M4TmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH3N\|VEUUN3ME2xMlU3PzF2IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SBC-1	MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS1fYdxUUN3ME2xMlU4QTh2IN88US=>	NYXH[2RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JiyoyeP-2003	NVWyZWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzrPHdKSzVyPUGuO\|M1PjZizszN	M{XYd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TE-5	NX3aZYRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vMSmlEPTB;MT63PVE{QSEQvF2=	NHLmb489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CAN	NEm0N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\Jc\|BKSzVyPUGuPFIzPTJizszN	NUjrU\|hKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SK-UT-1	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3i4UmlEPTB;Mj6xOlY6OyEQvF2=	MlT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
JVM-2	NEjhd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPKNJdKSzVyPUKuN\|YzQDRizszN	NHi5ZXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB771-HNC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TtOmlEPTB;Mj61O\|U2OSEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCCIT	M1jqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGr3cIlKSzVyPUKuPFY3OTZizszN	NYO0RWU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H2126	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXH0VXFJUUN3ME2yMlg4PTV{IN88US=>	NELMUmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
Calu-6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzjNXVFUUN3ME2zMlA2PzRzIN88US=>	M4G3WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SK-LMS-1	NHLIZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnTTWM2OD1\|LkGxPFg3KM7:TR?=	NYrhZphPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ARH-77	M1zWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml25TWM2OD1\|LkS2PVE2KM7:TR?=	MnfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB17	M4fPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTNwNkO4OFch\|ryP	NF7JUoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A253	NF;YclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PQcmlEPTB;Mz63N\|I1PiEQvF2=	NGOwSmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OPM-2	NX;aR4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnyTWM2OD12LkK3Olg2KM7:TR?=	M4PhSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MV-4-11	M4PrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXITWM2OD12LkO2OFU1KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SR	NES5[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Xx[GlEPTB;ND60PVk2PCEQvF2=	NGfyT5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KG-1	NY\tRllQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfYPY1KSzVyPUSuOlA5PDVizszN	M1X3Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
OCI-AML2	M{D3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYToSodRUUN3ME21Mlg3OTV2IN88US=>	MoPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
D-247MG	NVTBPId[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTZwMUK1NVkh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
DJM-1	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm3VIFWUUN3ME22MlQ5PTV6IN88US=>	NUniPXlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RPMI-6666	NYLoeGFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfYdWZKSzVyPUeuNlcxPjdizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KARPAS-45	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTdwNUG2O\|Eh\|ryP	MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LP-1	M4HTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTybHBQUUN3ME23MlU1Pzh{IN88US=>	MnvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
RS4-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXqUoZkUUN3ME23MlY2Pzh5IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
DU-4475	M4LoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\oS2lEPTB;OD6yNVY2OiEQvF2=	M3PlTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MONO-MAC-6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHaOGlKSzVyPUiuNlcxPjZizszN	NW[4OYNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-SNU-16	NGL4UWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHQRpRnUUN3ME24MlU3OTJ6IN88US=>	MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SJSA-1	NHfUNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L3bWlEPTB;OD63NlgxPSEQvF2=	NXTNS3RQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MMAC-SF	NXr4PVdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRThwN{mzNFch\|ryP	MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SK-NEP-1	NFixUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRThwOEmxOVUh\|ryP	NHe1co09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NHvLfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRThwOU[1Nlkh\|ryP	NH;SNpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SKM-1	NYrsO5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTlwMEG3N\|Qh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LB2241-RCC	NHPhTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmf6TWM2OD17LkCyNFEzKM7:TR?=	NHLodHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SIG-M5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;jZmc5UUN3ME25MlAzPDl\|IN88US=>	M4T6d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EVSA-T	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTlwMke3PVMh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
GT3TKB	NHTCfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTlwM{W1OFYh\|ryP	M2LyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NB6	NI\w[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTlwOUKyOVkh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EHEB	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFyLkC2OVYh\|ryP	NIn5OHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
HEL	M{G2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHQTZVCUUN3ME2xNE41Pzd4IN88US=>	NUjPeoJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ALL-PO	NGX3UVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGft[HVKSzVyPUGwMlc6OzhizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TGW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7JTWM2OD1zMT6yPFI5KM7:TR?=	NFHhfIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BC-3	NUCxRllpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MliwTWM2OD1zMj6xNVM5KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IA-LM	NXnSN5NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF{LkS0OFUh\|ryP	NWDDeGtuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
UACC-257	NEfRVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3UZnNpUUN3ME2xNk46OTl6IN88US=>	M3;zSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KP-N-YS	NELxUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TQcGlEPTB;MUKuPVI5OyEQvF2=	Ml:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
Raji	NEjIOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfRTWM2OD1zMz63OFk4KM7:TR?=	NVTFSGxFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SF539	NH3BPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M125[mlEPTB;MUOuPFU2PyEQvF2=	NYH0Tm1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DMS-153	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj2c2dKSzVyPUG0MlAxOjhizszN	MnG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
L-540	NIrwOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\2Oph7UUN3ME2xOU4xPjd{IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MN-60	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mor5TWM2OD1zNT6xPVc6KM7:TR?=	NGPUWmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
RPMI-8866	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLUb\|hKSzVyPUG3MlQ1PTRizszN	NWjZUohRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H510A	Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHjTWM2OD1zOT6zPVc{KM7:TR?=	NFXDd3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NB13	Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYriR\|UxUUN3ME2xPU41QDd5IN88US=>	NG\HeVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
HAL-01	NVfvXHR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUH1TGtnUUN3ME2xPU44PTR\|IN88US=>	M3S0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H720	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJyLkK3N\|Mh\|ryP	M2\4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
REH	M3e5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1qyV2lEPTB;MkCuOlM2PyEQvF2=	MmrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KNS-81-FD	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJ\|LkG0OkDPxE1?	M{THTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HC-1	M3fzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLDTWM2OD1{ND61OVUyKM7:TR?=	NVrhSlJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H2141	M3zwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDmfHBKUUN3ME2yOE44PzV2IN88US=>	NUTifVdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MOLT-4	NEXsT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv4TWM2OD1{Nj62O\|U{KM7:TR?=	NIDP[HQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OMC-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjzTWM2OD1{Nz6xOFIzKM7:TR?=	Mln1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LC-1F	MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3SZnpKSzVyPUK3MlMzPDVizszN	M{f5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1304	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ6LkG2Nlgh\|ryP	M4K1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BC-1	NG\2c\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPkfI5KSzVyPUK4MlY2OSEQvF2=	MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H64	NInPWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DkVmlEPTB;MkmuOlI2OyEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MOLT-16	NUTHSFRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofnTWM2OD1{OT62NlkzKM7:TR?=	MlvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
U-87-MG	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXNW\|JKSzVyPUOwMlc3PiEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
GAK	NXr4[WUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvmbZFKSzVyPUOxMlI3QDZizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
ES8	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPCPZlKSzVyPUOyMlEzPTJizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HCC1599	NWf1NnNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkT5TWM2OD1\|Mj6zN\|I2KM7:TR?=	M{nHS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EB-3	NYS2UoR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUexbIdIUUN3ME2zOE4{OTF5IN88US=>	NWi2UIJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HCC1187	M{Kxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDh[2tKSzVyPUO1MlgxPTJizszN	NIHtfZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SK-PN-DW	NHfmc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\4b49YUUN3ME2zOk4yQTR\|IN88US=>	NXTRSW9kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JVM-3	M33DUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTN5LkKzN\|gh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HCC2157	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTN5Lkm5OFYh\|ryP	NHfod449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A4-Fuk	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4W1S2lEPTB;M{iuNVAxQSEQvF2=	M4i1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
COR-L279	NWK0PVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTRyLkK4OVEh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
DEL	NXf3UFZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XYSWlEPTB;NEGuPVA5PiEQvF2=	NVjQNpoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H1395	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Dmb2lEPTB;NEKuNFE3OyEQvF2=	MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MHH-NB-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDGS21KSzVyPUSzMlA5OThizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H2107	NHq0OGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTR\|LkS4OFYh\|ryP	M{W4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NEC8	NFX5fGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXmTWM2OD12ND6zN\|Yh\|ryP	M1rlZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
COLO-684	NGfleGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXoW41iUUN3ME20Ok4zOjV6IN88US=>	NELmV2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LS-411N	NEnIWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;6U2ZMUUN3ME20PE41PzR6IN88US=>	MnjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	BMS-354825
Smiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4
NCT04115059	Recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 4 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 (AGL 1872, EI 275) is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib